Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 80, n° 6
pages 1509-1521 (juin 2019)
Doi : 10.1016/j.jaad.2018.08.061
accepted : 22 August 2018
Continuing Medical Education

Androgens in women : Hormone-modulating therapies for skin disease

Sarah Azarchi, BS a, Amanda Bienenfeld, BA a, Kristen Lo Sicco, MD b, Shari Marchbein, MD b, Jerry Shapiro, MD b, Arielle R. Nagler, MD b,
a New York University School of Medicine, New York, New York 
b Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 

Reprint requests: Arielle R. Nagler, MD, The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 240 E 38th St, 12th Fl, New York, NY 10016.Ronald O. Perelman Department of DermatologyNew York University School of Medicine240 E 38th St, 12th FlNew YorkNY10016

Androgen-mediated cutaneous disorders (AMCDs) in women, including acne, hirsutism, and female pattern hair loss, can be treated with hormone-modulating therapies. In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs, including combined oral contraceptives, spironolactone, finasteride, dutasteride, and flutamide. Available hormone-modulating treatments used for each AMCDs are reviewed, along with mechanisms of androgen modulation, safety profile, contraindications, monitoring parameters, and evidence of efficacy. Medications discussed include those that are approved by the US Food and Drug Administration for certain AMCDs and some that are used off-label. Despite the ubiquity of hormone-modulating therapies used for AMCDs, this review highlights the need for more rigorous studies to evaluate these therapies for acne, hirsutism, and female pattern hair loss.

The full text of this article is available in PDF format.

Key words : acne, androgenetic alopecia, androgen receptor, androgens, combined oral contraceptive, congenital adrenal hyperplasia, dutasteride, female pattern hair loss, finasteride, flutamide, hirsutism, polycystic ovary syndrome, spironolactone

 Date of release: June 2019
 Expiration date: June 2022
 Funding sources: None.
 Dr Shapiro has reported the following financial relationship with commercial interests: Aclaris Therapeutics Inc, Advisory Board, Honoraria; Applied Biology, Consultant, Honoraria; Bioniz Therapeutics, Advisory Board, Fees; Johnson & Johnson Consumer Products Company, Consultant, Honoraria; L'Oréal France, Consultant, Honoraria; Self RepliCel Life Sciences Founder, Stock; Samumed, LLC, Advisory Board, Honoraria; Allergan, Inc, Advisory Board, Honoraria; Bayer Consumer Healthcare Pharmaceuticals, Consultant, No Compensation Received; Cassiopea Spa, Advisory Board, No Compensation Received; Incyte Corporation, Consultant, No Compensation Received; RegenLab, Investigator, Grants/Research Funding,, Advisory Board, Stock; and Pfizer, Consultant; Honoraria. All other authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest.

© 2018  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline